In a report released today, Sachin Jain from Bank of America Securities reiterated a Buy rating on AstraZeneca, with a price target of p16,500.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sachin Jain has given his Buy rating due to a combination of factors that highlight AstraZeneca’s strong potential for growth. The company’s valuation appears attractive, with a projected price-to-earnings ratio that suggests room for upward movement. AstraZeneca is also positioned as one of the top stock picks for 2026, indicating confidence in its long-term performance.
Furthermore, the company’s robust pipeline is expected to deliver significant results in the coming years. Key developments in treatments for conditions such as non-small cell lung cancer and ATTR-CM are anticipated to drive sales growth. Despite some investor concerns, the potential rewards from these developments are seen as outweighing the risks. Additionally, AstraZeneca’s expected sales and earnings growth, coupled with efficient cost management, support the positive outlook for the stock.
In another report released on November 14, Bernstein also maintained a Buy rating on the stock with a p18,400.00 price target.